Fresenius SE & Co. KGaA (FSNUF)
OTCMKTS · Delayed Price · Currency is USD
46.21
-1.36 (-2.86%)
At close: Jul 16, 2025
Fresenius SE & Co. KGaA Revenue
Fresenius SE & Co. KGaA had revenue of 5.58B EUR in the quarter ending June 30, 2025, with 2.22% growth. This brings the company's revenue in the last twelve months to 22.26B, up 4.13% year-over-year. In the year 2024, Fresenius SE & Co. KGaA had annual revenue of 21.83B with 3.64% growth.
Revenue (ttm)
22.26B EUR
Revenue Growth
+4.13%
P/S Ratio
1.10
Revenue / Employee
126.10K EUR
Employees
176,486
Market Cap
28.74B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.83B | 766.00M | 3.64% |
| Dec 31, 2023 | 21.07B | -465.00M | -2.16% |
| Dec 31, 2022 | 21.53B | -15.99B | -42.61% |
| Dec 31, 2021 | 37.52B | 1.24B | 3.43% |
| Dec 31, 2020 | 36.28B | 868.00M | 2.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Fresenius SE & Co. KGaA News
- 1 day ago - Fresenius SE & Co. KGaA 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 1 day ago - Fresenius SE & Co. KGaA (FSNUF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Our U.S. investment has protected us - Fresenius CEO - CNBC
- 3 days ago - Fresenius Lifts Full-Year Sales Outlook as Revamp Gains Momentum - Financial Post
- 2 months ago - Fresenius: Healthy Portfolio Add - Seeking Alpha
- 3 months ago - Fresenius medical care outlines 2025 operating income growth targets amid strategic transformations - Seeking Alpha
- 3 months ago - Fresenius SE & Co. KGaA 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript - Seeking Alpha